NCT06462586CompletedPhase 3
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Lumateperone in the Acute Treatment of Patients With Manic Episodes or Manic Episodes With Mixed Features Associated With Bipolar I Disorder (Bipolar Mania)
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 354 (actual)
- First submitted
- 12 Jun 2024
- Start date
- 19 Jun 2024
- Primary completion date
- 24 Feb 2026
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Diseases
- Bipolar disorder
- NCT number
- NCT06462586
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 354
- From 19 Jun 2024 to the primary completion date, 24 Feb 2026
- 39 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during the course of his/her participation in the study or
- At Screening, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening; or
- At Screening, the patient has had 1 or more suicidal attempts within 2 years prior to Screening; or
- At Baseline, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the C-SSRS since the Screening Visit; or
- At Screening or Baseline, scores ≥ 4 on Item 10 (suicidal thoughts) on the rater administered Montgomery-Åsberg Depression Rating Scale (MADRS); or
- Considered to be an imminent danger to himself/herself or others.
Other illness
- Has a current primary DSM 5 psychiatric diagnosis other than bipolar disorder. These include:
- Schizophrenia, schizoaffective disorder, or other psychotic disorders;
- Dementia or other cognitive disorders;
- Intellectual disability;
- Moderate or severe substance use disorder (excluding for nicotine);
Other
- Experiencing first manic episode;
Who the study is looking for
- Able to provide written informed consent before the initiation of any study specific procedures;
- Male or female inpatient, between the ages of 18 and 75 years, inclusive;
- Meets the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM 5) criteria for bipolar I disorder with a current episode of mania or mania with mixed features with or without psychotic symptoms, as confirmed by a trained and Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT);
- YMRS total score ≥ 20 and a score of at least 4 on two of the following YMRS items: irritability, speech, content, and disruptive/aggressive behavior at Screening and Baseline;
- Hospitalized voluntarily before Screening or admitted to inpatient unit at Visit 1 with a primary diagnosis of mania but not \> 14 days before Screening. Hospital admission must be a result of the current manic episode.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (39)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.